The two together are critical to commercial success. Just getting rid of cardiotoxicity doesn’t get you a commercial drug as the developers of dexrazoxane discovered and as Neefjes has discovered trying to advance aclarubicin. Success will require showing in the clinic that bisantrene both improves doxorubicin anticancer activity AND makes it safer. This won’t be easy (nothing in clinical research ever is), but the potential makes it worth the effort.
The two together are critical to commercial success. Just...
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.61 |
Change
-0.055(3.31%) |
Mkt cap ! $273.4M | |||
| Open | High | Low | Value | Volume |
| $1.66 | $1.68 | $1.61 | $271.5K | 166.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1996 | $1.61 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.68 | 1305 | 2 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |